Tecentriq and Avastin first line of treatment in hepatocellular carcinoma

Share This Post

Swiss pharmaceutical giant Roche announced the PD-L1 tumor immunotherapy Tecentriq (atezolizumab) combined with Avastin (bevacizumab, bevacizumab) in the treatment of unresectable or advanced hepatocellular carcinoma (HCC) at ESMO 2018 in Munich, Germany ) The latest data from the Phase Ib clinical study (NCT02715531).

The efficacy evaluation group included all patients who received combination therapy and were followed for at least 16 weeks, with a median survival follow-up time of 7 months. In terms of complete response rate (CR), the CR assessed by INV according to RECIST v1.1 was 1 case (1%), the CR assessed by IRF according to RECIST v1.1 was 4 cases (5%), and the CR assessed by IRF according to HCC mRECIST was 8 cases (11%). The disease control rate (DCR, ie experienced remission or stable condition) was consistent in all forms of evaluation, INV’s DCR was 77% according to RECIST v1.1 (n = 56/73), IRF was based on RECIST v1.1 And the DCR according to HCC mRECIST is 75% (55/73). The median duration of remission (DOR) and overall survival (OS) have not been reached.

In the safety-evaluable group (n = 103), 27% of patients (n = 28/103) experienced grade 3-4 treatment-related adverse events and 2% (n = 2/103) experienced treatment-related grade 5 adverse events event. In addition to the safety profile of existing single drugs, no new safety signals related to combination therapy have been found.

In July this year, based on the overall data of the ongoing phase Ib study, the US FDA has granted Tecentriq + Avastin combination therapy as a first-line treatment for advanced or metastatic hepatocellular carcinoma (BTD). This is also the 23rd BTD awarded in Roche’s product portfolio to date and the 3rd BTD awarded by Tecentriq to date.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer
Colon cancer

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

The FDA has granted accelerated approval to Adagrasib combined with Cetuximab for treating KRAS G12C-mutated colorectal cancer. This approval is based on promising clinical trial results showing enhanced efficacy of the drug duo. Adagrasib, a KRAS inhibitor, and Cetuximab, an EGFR inhibitor, together target the cancer more effectively, offering new hope for patients with this specific genetic mutation, aiming to improve survival rates and treatment outcomes.

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
Endometrial cancer

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

The USFDA has approved Pembrolizumab combined with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval is based on clinical trial data showing significant improvements in patient outcomes. Pembrolizumab, an immune checkpoint inhibitor, works by enhancing the body’s immune response against cancer cells. This combination therapy offers a new and promising treatment option for patients facing this challenging and often aggressive cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy